OFI Invest Asset Management Invests $35,000 in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

OFI Invest Asset Management bought a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 155 shares of the biopharmaceutical company’s stock, valued at approximately $35,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Larson Financial Group LLC boosted its stake in shares of Alnylam Pharmaceuticals by 187.2% in the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 73 shares during the last quarter. HM Payson & Co. bought a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth approximately $59,000. AMF Tjanstepension AB bought a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth approximately $492,000. Generali Investments CEE investicni spolecnost a.s. bought a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth approximately $682,000. Finally, Andra AP fonden raised its holdings in shares of Alnylam Pharmaceuticals by 119.7% in the 4th quarter. Andra AP fonden now owns 27,900 shares of the biopharmaceutical company’s stock worth $6,565,000 after purchasing an additional 15,200 shares during the period. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Trading Down 4.7 %

Alnylam Pharmaceuticals stock opened at $233.07 on Tuesday. The stock has a market cap of $30.17 billion, a P/E ratio of -107.41 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The firm’s fifty day moving average price is $254.70 and its 200-day moving average price is $261.25. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, Director Phillip A. Sharp sold 11,250 shares of the company’s stock in a transaction dated Thursday, January 23rd. The shares were sold at an average price of $275.00, for a total transaction of $3,093,750.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CMO Pushkal Garg sold 1,752 shares of the company’s stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $251.00, for a total transaction of $439,752.00. Following the sale, the chief marketing officer now owns 15,705 shares of the company’s stock, valued at approximately $3,941,955. The trade was a 10.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 72,986 shares of company stock worth $20,397,849. Corporate insiders own 1.50% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently commented on ALNY. Wolfe Research cut shares of Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a report on Tuesday, November 12th. Canaccord Genuity Group lifted their price target on shares of Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the stock a “buy” rating in a report on Tuesday, February 18th. StockNews.com cut shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, January 9th. William Blair reaffirmed an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Wednesday, February 26th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $320.00 price target on shares of Alnylam Pharmaceuticals in a report on Wednesday, February 26th. One analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $304.26.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.